Gregory Bigot
France
Research Article
Efficacy and Safety of Insulin Glargine 300 U/mL in North Americans and Non-North Americans with Type 2 Diabetes: A Patient-Level Meta- Analysis of the EDITION 1, 2 and 3 Studies
Author(s): Irene Hramiak, Zubin Punthakee, Mélanie Groleau, Pasha Javadi, Gregory Bigot and Vincent WooIrene Hramiak, Zubin Punthakee, Mélanie Groleau, Pasha Javadi, Gregory Bigot and Vincent Woo
Objective: To assess efficacy and safety of insulin glargine 300 U/mL (Gla-300) versus (vs) insulin glargine 100 U/mL (Gla-100) in North American and non-North American people with type 2 diabetes mellitus on different background therapies.
Methods: A patient-level meta-analysis of three international studies (EDITION 1, 2 and 3) was performed to examine glycemic control and hypoglycemia over 6 months in 2496 participants including 1420 participants in a North American sub-population (Gla-300, N=700; Gla-100, N=720). Endpoints included change in glycated hemoglobin (HbA1c), percentage of patients at target HbA1c at Month 6, incidence and rate of hypoglycemic events, change in body weight and insulin dose, as well as incidence of adverse events.
Results: Mean change in HbA1c was comparable for Gla-300 and Gla100 in both r.. View More»
